How to buy VistaGen Therapeutics (VTGN) stock

VistaGen Therapeutics, Inc is a biotechnology business based in the US. VistaGen Therapeutics shares (VTGN) are listed on the NASDAQ and all prices are listed in US Dollars. VistaGen Therapeutics employs 21 staff and has a trailing 12-month revenue of around 0.00.

VistaGen Therapeutics stock price (NASDAQ: VTGN)

Use our graph to track the performance of VTGN stocks over time.

VistaGen Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$2.63
52-week range	$0.56 - $3.55
50-day moving average	$2.86
200-day moving average	$2.42
Wall St. target price	$6.75
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.83

Buy VistaGen Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy VistaGen Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of VistaGen Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

VistaGen Therapeutics price performance over time

Historical closes compared with the close of $2.63 from 2021-05-26

1 week (2021-07-17)	N/A
1 month (2021-06-28)	-7.39%
3 months (2021-04-28)	7.79%
6 months (2021-01-24)	N/A

1 year (2020-07-24)	N/A
2 years (2019-07-24)	N/A
3 years (2018-07-24)	N/A
5 years (2016-07-24)	N/A

VistaGen Therapeutics financials

Revenue TTM	$1.1 million
Gross profit TTM	$1.1 million
Return on assets TTM	-19.66%
Return on equity TTM	-36.78%
Profit margin	0%
Book value	$0.51
Market capitalisation	$556.9 million

TTM: trailing 12 months

Shorting VistaGen Therapeutics shares

There are currently 12.3 million VistaGen Therapeutics shares held short by investors – that's known as VistaGen Therapeutics's "short interest". This figure is 88.5% up from 6.5 million last month.

There are a few different ways that this level of interest in shorting VistaGen Therapeutics shares can be evaluated.

VistaGen Therapeutics's "short interest ratio" (SIR)

VistaGen Therapeutics's "short interest ratio" (SIR) is the quantity of VistaGen Therapeutics shares currently shorted divided by the average quantity of VistaGen Therapeutics shares traded daily (recently around 3.2 million). VistaGen Therapeutics's SIR currently stands at 3.83. In other words for every 100,000 VistaGen Therapeutics shares traded daily on the market, roughly 3830 shares are currently held short.

However VistaGen Therapeutics's short interest can also be evaluated against the total number of VistaGen Therapeutics shares, or, against the total number of tradable VistaGen Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VistaGen Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 VistaGen Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.081% of the tradable shares (for every 100,000 tradable VistaGen Therapeutics shares, roughly 81 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against VistaGen Therapeutics.

Find out more about how you can short VistaGen Therapeutics stock.

VistaGen Therapeutics share dividends

We're not expecting VistaGen Therapeutics to pay a dividend over the next 12 months.

Have VistaGen Therapeutics's shares ever split?

VistaGen Therapeutics's shares were split on a 1:20 basis on 13 August 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VistaGen Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for VistaGen Therapeutics shares which in turn could have impacted VistaGen Therapeutics's share price.

VistaGen Therapeutics share price volatility

Over the last 12 months, VistaGen Therapeutics's shares have ranged in value from as little as $0.5551 up to $3.55. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VistaGen Therapeutics's is 0.8923. This would suggest that VistaGen Therapeutics's shares are less volatile than average (for this exchange).

VistaGen Therapeutics overview

VistaGen Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd. ; license and option agreements with Pherin Pharmaceuticals, Inc.

Frequently asked questions

What percentage of VistaGen Therapeutics is owned by insiders or institutions?
Currently 0.227% of VistaGen Therapeutics shares are held by insiders and 60.734% by institutions. How many people work for VistaGen Therapeutics?
Latest data suggests 21 work at VistaGen Therapeutics. When does the fiscal year end for VistaGen Therapeutics?
VistaGen Therapeutics's fiscal year ends in March. Where is VistaGen Therapeutics based?
VistaGen Therapeutics's address is: 343 Allerton Avenue, South San Francisco, CA, United States, 94080 What is VistaGen Therapeutics's ISIN number?
VistaGen Therapeutics's international securities identification number is: US92840H2022 What is VistaGen Therapeutics's CUSIP number?
VistaGen Therapeutics's Committee on Uniform Securities Identification Procedures number is: 92840H103